Sirolimus to prevent first seizures in babies with TSC
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This Phase 2 study tests whether sirolimus (a targeted medicine) can stop or slow the start of seizures in very young babies diagnosed with tuberous sclerosis complex (TSC). If seizures are prevented early, it may also help protect early brain development.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby must be under 7 months old when starting the study (born at least 39 weeks corrected age).
- Baby must have a confirmed TSC diagnosis (from clinical exam or genetic testing).
- Baby must not have had seizures yet, including on a baseline EEG test.
- Baby must not be taking anti-seizure medicines, sirolimus/other mTOR medicines, or special seizure diets right now.
- Baby must not have had certain procedures or major birth complications that greatly raise seizure/development risk.
- Baby must not have needed mTOR treatment for specific TSC problems (like SEGA or AML).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether rapamycin (compared with a placebo) can reduce seizures caused by tuberous sclerosis complex (TSC) that have not been controlled by usual medicines. If you qualify, you may be helping doctors find a safer and more effective option for seizure control.
This study tests an investigational drug called AV078 for people with tuberous sclerosis complex (TSC) whose seizures are not controlled by at least two current medications. The goal is to see if AV078 can reduce seizure frequency safely, and participants continue their usual seizure medications during the trial.
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
This trial tests a full-spectrum cannabis extract to see if it reduces seizures in people with tuberous sclerosis complex (TSC) whose seizures have not been controlled by other treatments. If it works, it could offer a new option for managing hard-to-treat epilepsy.
Hear when a new Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.